|Day Low/High||37.31 / 37.60|
|52 Wk Low/High||32.32 / 39.43|
Jim Cramer says this market is all about being opportunistic, about being willing to fight the tide.
From Coca-Cola to Pfizer, these blue chips offer well-supported dividend payouts.
This market is all about being opportunistic.
Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study ( NCT03587116) to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.
First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC
The most recent short interest data has been released for the 06/29/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Here's what you need to know now for Wednesday, July 11.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks from the floor of the New York Stock Exchange.
For Pfizer, China is third largest market and a growing area of concern.
We believe the company has double-digit total return potential at its current price.
The Dow tumbled Wednesday, losing ground for the first session in five, after the U.S. threatened additional tariffs on $200 billion worth of China-made goods.
Pfizer reorganization could pave way for the company to spin off businesses.
Pfizer announced plans Wednesday to reorganize into three units.
The stock faces a lot of headwinds on a day when markets are trying to surmount trade-war woes.
The changes will take effect at the start of 2019.
The bets are coming off one table and going to another amid the tariff news, much to the consternation of the sideliners.
U.S. stock futures fall sharply on Wednesday, after the White House publishes a list of $200 billion worth of China-made goods it says will be hit with fresh tariffs; Twenty-First Century Fox increases its bid to buy Britain's Sky; Pfizer to 'defer' raising drug prices following talks with Donald Trump.
Pfizer bowed to pressure from President Donald Trump late Tuesday by agreeing to temporarily rollback a planned price increase following Tweets suggesting the group "should be ashamed".
Here are the business stories you must know as U.S. stock futures fall sharply.
Pfizer Inc. (NYSE:PFE) today announced it will organize the company into three businesses: a science-based Innovative Medicines business which will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables; an...
Following an extensive discussion with President Trump today, Pfizer's Chairman and CEO Ian Read announced that it will defer the company's price increases that were effective on July 1 to give the president an opportunity to work on his blueprint to...
President Trump criticized Pfizer and others in a tweet on July 9, saying they hiked prices 'for no reason.'
The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.
While President Trump pledged last month that pharma companies would decide to voluntarily aggress to 'massive' drops in drug prices, clearly nobody told Pfizer.
Why study charts? Because they're like footprints at the scene of the crime, clues to what the big money managers are likely thinking, Jim Cramer says.
Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.